Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 884

1.

Applying Medical Device Informatics to Enable Safe and Secure Interoperable Systems: Medical Device Interface Data Sheets.

Goldman JM, Weininger S, Jaffe MB.

Anesth Analg. 2019 Nov 21. doi: 10.1213/ANE.0000000000004251. [Epub ahead of print]

PMID:
31804406
2.

Establishing a Ventilator-Heart Lung Machine Communication Bridge to Mitigate Errors when Weaning from Bypass.

Rance G, Arney D, Srey R, Goldman JM, Zenati MA.

J Extra Corpor Technol. 2019 Mar;51(1):38-40.

3.

A Novel Interoperable Safety System for Improved Coordination and Communication in Cardiac Surgery.

Arney D, Rance G, Rithy S, Goldman JM, Zenati MA.

OR 2.0 Context Aware Oper Theaters Comput Assist Robot Endosc Clin Image Based Proced Skin Image Anal (2018). 2018 Sep;11041:39-45. doi: 10.1007/978-3-030-01201-4_5. Epub 2018 Oct 2.

4.

Development of an Interactive Dashboard to Analyze Cognitive Workload of Surgical Teams During Complex Procedural Care.

Dias RD, Conboy HM, Gabany JM, Clarke LA, Osterweil LJ, Avrunin GS, Arney D, Goldman JM, Riccardi G, Yule SJ, Zenati MA.

IEEE Int Interdiscip Conf Cogn Methods Situat Aware Decis Support. 2018 Jun;2018:77-82. doi: 10.1109/COGSIMA.2018.8423995. Epub 2018 Aug 2.

5.

Intelligent Interruption Management System to Enhance Safety and Performance in Complex Surgical and Robotic Procedures.

Dias RD, Conboy HM, Gabany JM, Clarke LA, Osterweil LJ, Arney D, Goldman JM, Riccardi G, Avrunin GS, Yule SJ, Zenati MA.

OR 2.0 Context Aware Oper Theaters Comput Assist Robot Endosc Clin Image Based Proced Skin Image Anal (2018). 2018 Sep;11041:62-68. doi: 10.1007/978-3-030-01201-4_8. Epub 2018 Oct 2.

6.

Representative Scale-Down Lyophilization Cycle Development Using a Seven-Vial Freeze-Dryer (MicroFD®).

Goldman JM, Chen X, Register JT, Nesarikar V, Iyer L, Wu Y, Mugheirbi N, Rowe J.

J Pharm Sci. 2019 Apr;108(4):1486-1495. doi: 10.1016/j.xphs.2018.11.018. Epub 2018 Nov 20.

PMID:
30468831
7.

Toward Improving Surgical Outcomes by Incorporating Cognitive Load Measurement into Process-Driven Guidance.

Avrunin GS, Clarke LA, Conboy HM, Osterweil LJ, Dias RD, Yule SJ, Goldman JM, Zenati MA.

Softw Eng Healthc Syst SEHS IEEE ACM Int Workshop. 2018 May;2018:2-9. doi: 10.1145/3194696.3194705.

8.

Optimization of Primary Drying in Lyophilization During Early-Phase Drug Development Using a Definitive Screening Design With Formulation and Process Factors.

Goldman JM, More HT, Yee O, Borgeson E, Remy B, Rowe J, Sadineni V.

J Pharm Sci. 2018 Oct;107(10):2592-2600. doi: 10.1016/j.xphs.2018.06.001. Epub 2018 Jun 8.

PMID:
29890172
9.

Readmission rate after ultrafiltration in acute decompensated heart failure: a systematic review and meta-analysis.

Siddiqui WJ, Kohut AR, Hasni SF, Goldman JM, Silverman B, Kelepouris E, Eisen HJ, Aggarwal S.

Heart Fail Rev. 2017 Nov;22(6):685-698. doi: 10.1007/s10741-017-9650-3. Review.

PMID:
28900774
10.

Method to assess component contribution to toxicity of complex mixtures: Assessment of puberty acquisition in rats exposed to disinfection byproducts.

Parvez S, Rice GE, Teuschler LK, Simmons JE, Speth TF, Richardson SD, Miltner RJ, Hunter ES 3rd, Pressman JG, Strader LF, Klinefelter GR, Goldman JM, Narotsky MG.

J Environ Sci (China). 2017 Aug;58:311-321. doi: 10.1016/j.jes.2017.05.042. Epub 2017 Jun 7.

PMID:
28774622
11.

Cognitive Support During High-Consequence Episodes of Care in Cardiovascular Surgery.

Conboy HM, Avrunin GS, Clarke LA, Osterweil LJ, Christov SC, Goldman JM, Yule SJ, Zenati MA.

IEEE Int Interdiscip Conf Cogn Methods Situat Aware Decis Support. 2017 Mar;2017. doi: 10.1109/COGSIMA.2017.7929610. Epub 2017 May 18.

12.

OpenICE medical device interoperability platform overview and requirement analysis.

Arney D, Plourde J, Goldman JM.

Biomed Tech (Berl). 2018 Feb 23;63(1):39-47. doi: 10.1515/bmt-2017-0040.

PMID:
28734113
13.

In Response.

Goldman JM.

Anesth Analg. 2017 Aug;125(2):707-708. doi: 10.1213/ANE.0000000000002246. No abstract available.

PMID:
28654431
14.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

15.

The Importance of State and Context in Safe Interoperable Medical Systems.

Weininger S, Jaffe MB, Robkin M, Rausch T, Arney D, Goldman JM.

IEEE J Transl Eng Health Med. 2016 Aug 8;4:2800110. eCollection 2016.

16.
17.

Capturing Essential Information to Achieve Safe Interoperability.

Weininger S, Jaffe MB, Rausch T, Goldman JM.

Anesth Analg. 2017 Jan;124(1):83-94.

18.

BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.

Goldman JM, Gray JE.

Cancer Genet. 2015 Jun;208(6):351-4. doi: 10.1016/j.cancergen.2015.04.001. Epub 2015 Apr 7.

PMID:
26066373
19.

The heterogeneity and diversity of hypertension in CKD.

Goldman JM, Cohen DL, Sim JJ.

Adv Chronic Kidney Dis. 2015 Mar;22(2):86-7. doi: 10.1053/j.ackd.2014.12.003. No abstract available.

PMID:
25704343
20.

Reproductive toxicity of a mixture of regulated drinking-water disinfection by-products in a multigenerational rat bioassay.

Narotsky MG, Klinefelter GR, Goldman JM, DeAngelo AB, Best DS, McDonald A, Strader LF, Murr AS, Suarez JD, George MH, Hunter ES, Simmons JE.

Environ Health Perspect. 2015 Jun;123(6):564-70. doi: 10.1289/ehp.1408579. Epub 2015 Feb 19.

21.

Solving the interoperability challenge: safe and reliable information exchange requires more from product designers.

Goldman JM.

IEEE Pulse. 2014 Nov-Dec;5(6):37-9. doi: 10.1109/MPUL.2014.2355307. No abstract available.

PMID:
25415883
22.

The Design of Safe Networked Supervisory Medical Systems Using Organ-Centric Hierarchical Control Architecture.

Kang W, Sha L, Berlin RB Jr, Goldman JM.

IEEE J Biomed Health Inform. 2015 May;19(3):1077-86.

PMID:
24988597
23.

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM.

Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. Review. No abstract available.

24.

Chronic myeloid leukemia in India.

Goldman JM.

Indian J Med Paediatr Oncol. 2013 Jul;34(3):147-8. doi: 10.4103/0971-5851.123700. No abstract available.

25.

[History of chronic myeloid leukemia: a paradigm in the treatment of cancer].

Gonon-Demoulian R, Goldman JM, Nicolini FE.

Bull Cancer. 2014 Jan 1;101(1):56-67. doi: 10.1684/bdc.2013.1876. French.

PMID:
24491668
26.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.

27.

What does MRD in leukemia really mean?

Goldman JM, Gale RP.

Leukemia. 2014 May;28(5):1131. doi: 10.1038/leu.2013.318. Epub 2013 Oct 30. No abstract available.

PMID:
24170026
28.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L.

Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.

PMID:
24117365
29.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

30.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

31.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D.

Blood. 2013 Sep 12;122(11):1923-34. doi: 10.1182/blood-2013-03-492181. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

32.

Comprehensive assessment of a chlorinated drinking water concentrate in a rat multigenerational reproductive toxicity study.

Narotsky MG, Klinefelter GR, Goldman JM, Best DS, McDonald A, Strader LF, Suarez JD, Murr AS, Thillainadarajah I, Hunter ES 3rd, Richardson SD, Speth TF, Miltner RJ, Pressman JG, Teuschler LK, Rice GE, Moser VC, Luebke RW, Simmons JE.

Environ Sci Technol. 2013 Sep 17;47(18):10653-9. doi: 10.1021/es402646c. Epub 2013 Aug 28.

PMID:
23909560
33.

What challenges remain in chronic myeloid leukemia research?

Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM.

Haematologica. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381. No abstract available.

34.

Atrazine-induced elevation or attenuation of the LH surge in the ovariectomized, estrogen-primed female rat: role of adrenal progesterone.

Goldman JM, Davis LK, Murr AS, Cooper RL.

Reproduction. 2013 Aug 12;146(4):305-14. doi: 10.1530/REP-13-0011. Print 2013 Oct.

PMID:
23847262
35.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.

Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Review.

36.

High affinity γPNA sandwich hybridization assay for rapid detection of short nucleic acid targets with single mismatch discrimination.

Goldman JM, Zhang LA, Manna A, Armitage BA, Ly DH, Schneider JW.

Biomacromolecules. 2013 Jul 8;14(7):2253-61. doi: 10.1021/bm400388a. Epub 2013 Jun 18.

PMID:
23777445
37.

Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Gale RP, Goldman JM.

Acta Haematol. 2013;130(3):192-5. doi: 10.1159/000351957. Epub 2013 Jun 13. No abstract available.

PMID:
23774684
38.

The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.

Goldman JM.

Biol Blood Marrow Transplant. 2013 May;19(5):679-80. doi: 10.1016/j.bbmt.2013.02.016. Epub 2013 Mar 1. No abstract available.

39.

Ponatinib for chronic myeloid leukemia.

Goldman JM.

N Engl J Med. 2012 Nov 29;367(22):2148-9. doi: 10.1056/NEJMe1210796. No abstract available.

PMID:
23190226
40.

Is imatinib still an acceptable first-line treatment for CML in chronic phase?

Goldman JM, Marin D.

Oncology (Williston Park). 2012 Oct;26(10):901-7.

41.

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.

Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI.

Leuk Lymphoma. 2013 Jun;54(6):1151-8. doi: 10.3109/10428194.2012.745524. Epub 2012 Dec 10. Review.

42.

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

Cortes J, Goldman JM, Hughes T.

J Natl Compr Canc Netw. 2012 Oct 1;10 Suppl 3:S1-S13.

PMID:
23055247
43.

Biology of CML stem cells: the basis for clinical heterogeneity?

Goldman JM, Gordon M, Bazeos A, Marin D.

Leuk Suppl. 2012 Aug;1(Suppl 2):S43-5. doi: 10.1038/leusup.2012.23. Epub 2012 Aug 9.

44.

Simulation of medical device network performance and requirements for an integrated clinical environment.

Arney D, Goldman JM, Bhargav-Spantzel A, Basu A, Taborn M, Pappas G, Robkin M.

Biomed Instrum Technol. 2012 Jul-Aug;46(4):308-15. doi: 10.2345/0899-8205-46.4.308. No abstract available.

45.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K.

Blood. 2012 Jul 19;120(3):697-8. doi: 10.1182/blood-2012-04-421016. No abstract available.

46.

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S.

Blood. 2012 Jul 12;120(2):291-4. doi: 10.1182/blood-2012-01-407486. Epub 2012 May 29.

PMID:
22645182
47.

Design of an x-ray / ventilator synchronization system in an integrated clinical environment.

Arney D, Bhatia K, Bhatia S, Sutton M, Rausch T, Karlinsky J, Goldman JM.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:8203-6. doi: 10.1109/IEMBS.2011.6092023.

PMID:
22256246
48.

Chronic myeloid leukemia: the basis of treatment for tomorrow.

Carella AM, Goldman JM, Martinelli G, Melo JV, Perrotti D.

Haematologica. 2011 Dec;96(12):1737-9. doi: 10.3324/haematol.2011.052571. No abstract available.

49.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L.

J Clin Oncol. 2012 Jan 20;30(3):232-8. doi: 10.1200/JCO.2011.38.6565. Epub 2011 Nov 7.

50.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.

Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A.

Br J Haematol. 2012 Apr;157(1):125-7. doi: 10.1111/j.1365-2141.2011.08906.x. Epub 2011 Nov 3. No abstract available.

Supplemental Content

Loading ...
Support Center